US 10626173
Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR
granted A61KA61K38/00A61K38/08
Quick answer
US patent 10626173 (Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K38/00, A61K38/08, A61K38/10, A61K38/22